Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 9월 06

Recursion Pharmaceuticals Inc

RXRXNASDAQ
Trade with Public
Trade with Public
$3.63
0.195.52%
가까이에: Sep 4, 5:00 PM EST
$3.65
0.01960.54%
시간외: Sep 4, 7:58 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Recursion Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Recursion Pharmaceuticals (RXRX).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

3Buy
4Hold
Consensus RatingOverweight# Analysts7Avg. Consensus PT$8Upside to Avg. PT+114.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 14, 2026Morgan StanleyVikram PurohitPT RaiseEqual-Weight$5→$6
May 7, 2026NeedhamGil BlumMaintainedBuy$8
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Equal-Weight and raises the price target from $5 to $5.5.
Benzinga Newsdesk

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.
Priya Nigam

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $11 to $10.
Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

B of A Securities analyst Michael Ryskin maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Neutral and lowers the price target from $7 to $6.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved